Singapore: Royal Bank of Scotland chief, Mr Philip Hampton, is getting on board of drug giant GlaxoSmithKline as non-executive director starting from 1 January 2015. He will also be appointed as the deputy chairman with effect from 1 April 2015.

Mr Hampton will succeed Mr Christopher Gent as non-executive chairman with effect from 1 September 2015.

The decision comes after GSK faced severe criticism in China for fraudulent activities.

Sir Deryck Maughan said, "We are delighted Sir Philip is joining the GSK Board to succeed Sir Christopher as Chairman. GSK is well positioned for the future, with a strong R&D pipeline and the impending transformative asset transaction with Novartis announced in April. Sir Philip's appointment provides a clear plan of succession and we welcome him to our Board."

Sir Philip has been chairman of Royal Bank of Scotland Group since February 2009.